Cardiff Competitors
| CRDF Stock | USD 1.61 0.00 0.00% |
Cardiff Oncology vs Innate Pharma Correlation
Very good diversification
The correlation between Cardiff Oncology and IPHA is -0.26 (i.e., Very good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Cardiff Oncology and IPHA in the same portfolio, assuming nothing else is changed.
Moving against Cardiff Stock
| 0.57 | JUMP | Leveljump Healthcare Corp | PairCorr |
| 0.46 | ALT | Altimmune | PairCorr |
| 0.36 | IMRN | Immuron Ltd ADR | PairCorr |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Cardiff Oncology's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Cardiff Oncology Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Cardiff Oncology and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Cardiff and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Cardiff Oncology does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Cardiff Stock performing well and Cardiff Oncology Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Cardiff Oncology's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| APLT | 7.02 | (2.67) | 0.00 | (0.76) | 0.00 | 10.00 | 83.66 | |||
| CRBP | 2.74 | (0.70) | 0.00 | (0.64) | 0.00 | 5.95 | 16.04 | |||
| ELTX | 2.79 | (0.24) | 0.00 | (0.06) | 0.00 | 5.76 | 21.98 | |||
| MOLN | 2.80 | 0.27 | 0.05 | 4.50 | 3.29 | 4.77 | 26.47 | |||
| FBRX | 5.82 | 1.63 | 0.22 | (3.12) | 5.99 | 16.12 | 40.19 | |||
| PEPG | 4.94 | 0.14 | 0.01 | 0.54 | 6.23 | 10.14 | 27.05 | |||
| RANI | 3.74 | (0.93) | 0.00 | (0.29) | 0.00 | 9.28 | 26.23 | |||
| MIST | 3.24 | (0.06) | (0.01) | 0.02 | 4.39 | 6.15 | 34.31 | |||
| SAVA | 4.08 | (0.74) | 0.00 | (0.21) | 0.00 | 9.05 | 35.02 | |||
| IPHA | 2.31 | (0.10) | 0.00 | (0.39) | 0.00 | 3.41 | 39.49 |
Cross Equities Net Income Analysis
Compare Cardiff Oncology and related stocks such as Applied Therapeutics, Corbus Pharmaceuticals, and Elicio Therapeutics Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| APLT | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (16.5 M) | (45.4 M) | (93 M) | (104.6 M) | (82.5 M) | (119.8 M) | (105.6 M) | (95.1 M) | (99.8 M) |
| CRBP | (887) | (887) | (887) | (602.4 K) | (2.5 M) | (8.9 M) | (20 M) | (32.4 M) | (55.7 M) | (71.5 M) | (111.3 M) | (45.6 M) | (55.8 M) | (44.6 M) | (40.2 M) | (36.2 M) | (38 M) |
| ELTX | 307.3 K | 307.3 K | 307.3 K | 632.2 K | (20 M) | (20 M) | (20 M) | (20 M) | (20 M) | (40.7 M) | (80.1 M) | (26.4 M) | (28.2 M) | (35.2 M) | (51.9 M) | (46.7 M) | (49 M) |
| MOLN | 7.1 M | 7.1 M | 7.1 M | 7.1 M | (2.3 M) | (148.8 K) | (18.6 M) | (25.4 M) | (37 M) | (36.3 M) | (62.8 M) | (63.8 M) | 117.9 M | (62 M) | (54 M) | (48.6 M) | (46.2 M) |
| FBRX | (23.1 M) | (23.1 M) | (23.1 M) | (23.1 M) | (23.1 M) | (23.1 M) | (33.5 M) | (38.9 M) | (49 M) | (4.1 M) | (46.5 M) | (21.7 M) | (13.9 M) | (31.5 M) | (35.5 M) | (40.8 M) | (42.8 M) |
| PEPG | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.9 M) | (27.3 M) | (69.1 M) | (78.6 M) | (90 M) | (81 M) | (76.9 M) |
| RANI | (26.6 M) | (26.6 M) | (26.6 M) | (26.6 M) | (26.6 M) | (26.6 M) | (26.6 M) | (26.6 M) | (26.6 M) | (26.6 M) | (16.7 M) | (8.3 M) | (30.6 M) | (34 M) | (30 M) | (27 M) | (28.4 M) |
| MIST | (8.1 M) | (8.1 M) | (8.1 M) | (8.1 M) | (8.1 M) | (8.1 M) | (8.1 M) | (8.1 M) | (23.2 M) | (55.2 M) | (50 M) | (42.9 M) | (57.1 M) | (59.7 M) | (41.5 M) | (37.4 M) | (39.2 M) |
| SAVA | (4.5 M) | (2.6 M) | (3.4 M) | 31.5 M | (12.4 M) | (14.1 M) | (14.8 M) | (11.9 M) | (6.6 M) | (4.2 M) | (6.3 M) | (31.8 M) | (72.5 M) | (97.2 M) | (24.3 M) | (21.9 M) | (23 M) |
| IPHA | (6.1 M) | (7 M) | (3.2 M) | (2.9 M) | (19.6 M) | (6.7 M) | 12.6 M | (48.4 M) | 3 M | (20.8 M) | (64 M) | (52.8 M) | (58.1 M) | (7.6 M) | (49.5 M) | (44.5 M) | (42.3 M) |
Cardiff Oncology and related stocks such as Applied Therapeutics, Corbus Pharmaceuticals, and Elicio Therapeutics Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Cardiff Oncology financial statement analysis. It represents the amount of money remaining after all of Cardiff Oncology operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Cardiff Oncology Competitive Analysis
The better you understand Cardiff Oncology competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Cardiff Oncology's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Cardiff Oncology's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Cardiff Oncology Competition Performance Charts
Five steps to successful analysis of Cardiff Oncology Competition
Cardiff Oncology's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Cardiff Oncology in relation to its competition. Cardiff Oncology's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Cardiff Oncology in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Cardiff Oncology's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Cardiff Oncology, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Cardiff Oncology position
In addition to having Cardiff Oncology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Energy Funds Thematic Idea Now
Energy Funds
Funds or Etfs investing in energy sector, natural resources, and ecology. The Energy Funds theme has 39 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Energy Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Cardiff Oncology Correlation with its peers. For more detail on how to invest in Cardiff Stock please use our How to Invest in Cardiff Oncology guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Can Biotechnology industry sustain growth momentum? Does Cardiff have expansion opportunities? Factors like these will boost the valuation of Cardiff Oncology. Projected growth potential of Cardiff fundamentally drives upward valuation adjustments. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Cardiff Oncology demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Earnings Share (0.79) | Revenue Per Share | Quarterly Revenue Growth (0.27) | Return On Assets | Return On Equity |
Understanding Cardiff Oncology requires distinguishing between market price and book value, where the latter reflects Cardiff's accounting equity. The concept of intrinsic value - what Cardiff Oncology's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Market sentiment, economic cycles, and investor behavior can push Cardiff Oncology's price substantially above or below its fundamental value.
It's important to distinguish between Cardiff Oncology's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cardiff Oncology should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Cardiff Oncology's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.